HIF-2α activity mediated by the COX2/PGE2 axis was found to be associated with the activation of TGF-α/EGFR, which in turn promotes HCC development and reduces the sensitivity to sorafenib. The gene discussed is EPAS1; the disease is hepatocellular carcinoma.